For instance, fibroblast growth factor receptor 2 (FGFR2) rearrangements in cholangiocarcinoma predict tumor sensitivity to FGFR2 inhibitors (Vogel et al., 2023). This evidence concerns the gene FGFR2 and neoplasm.